EMvision Medical Devices Limited (ASX:EMV)

The annual report for EMVision Medical Devices Ltd for the year ending 30 June 2026 provides a comprehensive overview of the company's financial performance and strategic initiatives. The company reported a total revenue and income of $8,849,085 with a significant portion coming from R&D rebates and grant income. Despite these revenues, EMVision incurred a net loss after tax of $8,316,350, reflecting ongoing investments in research and development. The report highlights the issuance of additional equity and share-based payments to bolster capital and incentivize key personnel. As of 30 June 2026, the company held net assets of $15,768,711, supported by increased issued capital and reserves. The document also outlines the financial strategy involving borrowings under the NSW Medical Devices Fund aimed at fostering innovation and product development. The directors' report includes detailed financial statements, share and option holdings of key management personnel, and an analysis of the company's financial position focusing on liabilities and equity.